This is a registry study to evaluate the long-term safety and effectiveness of an active drug in pediatric patients with moderately to severely active CD who are treated as recommended in the local product label.
This is a registry study to evaluate the long-term safety and effectiveness of an active drug in patients with moderately to severely active UC who are treated as recommended in the product label.
The purpose of this study is to evaluate treatment of advanced Parkinson's Disease (PD) patients on an active drug intestinal gel monotherapy in a routine clinical setting.
Canadian Real Life Evaluation of the Effect of Diet and Exercise in Prostate Cancer Patients Managed with an active drug.
The purpose of this study is to describe the impact of treatment with an active drug on work related productivity and economic burden in patients with Rheumatoid Arthritis (RA) treated in Canada.
This is an open-label, postmarketing, observational study to document health outcomes, in Canadian patients with advanced Parkinson's disease and long-term treatment with an active drug (active drug intestinal gel).
To evaluate the real-life effect after 1 year of an active drug treatment on psychological distress/depression symptoms in moderate-to-severe Ulcerative Colitis (UC) patients.
This study assesses an active drug real-life effectiveness in the management of dermatological manifestations of moderate to severe Hidradenitis Suppurativa (HS).
This is a multi-center study that explores the relationship between recapture of response with escalation to weekly active drug and trough concentration of the active drug before escalation in patients experiencing lack of response (LOR).
A study to assess the real-life management and use of healthcare resources during the initiation of:
- Active drug in combination with rituximab is indicated for the treatment of adult participants with chronic lymphocytic leukemia (CLL) who